Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Trump Says Anthropic No Longer Seen as National Security Threat 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
RALEIGH, N.C., Feb. 04, 2016 -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2015 results after the market closes on Wednesday, February 24, 2016. The Company will also host a conference call on Thursday, February 25, 2016 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 46737204. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 46737204.
A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, the presentation and an audio playback of the call will be available at the same website.
ABOUT PRA HEALTH SCIENCES
At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. As a top five CRO, PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.
INVESTOR INQUIRIES: [email protected] INQUIRIES: Christine Rogers, Manager – Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +919.786.8463
